By vgreene, 20 October, 2020 Study considerations not peer reviewed randomized interim analysis significant proportion of pts received other potential treatments for COVID varied by tx arm sx duration not reported excluded peds pts
By vgreene, 20 October, 2020 Overall 28-day mortality 12%; no significant difference in reduced mortality w/ death rate ratio vs control: RDV (RR 0.95, 95% CI 0.81-1.11), HCQ (RR 1.19, 95% CI 0.89-1.59); LPV/r (RR 1.00, 95% CI 0.79-1.25) and IFN (RR 1.16, 95% CI 0.96-1.39); no signif
By vgreene, 20 October, 2020 Multinational, randomized study; 11,266 hospitalized pts (~10% ventilated) w/ COVID-19 received either RDV (n=2,750), HCQ (n=954), LPV/r (n=1,411), IFN beta 1a + LPV/r (n=651), IFN beta 1a (n=1,412) or SOC (n=4,088); pts could receive other therapies incl
By vgreene, 20 October, 2020 Repurposed Antiviral Drugs for Covid 19 Interim WHO Solidarity Trial Results
By vgreene, 20 October, 2020 Study considerations not peer reviewed randomized interim analysis significant proportion of pts received other potential treatments for COVID varied by tx arm sx duration not reported excluded peds pts
By vgreene, 20 October, 2020 Overall 28-day mortality 12%; no significant difference in reduced mortality w/ death rate ratio vs control: RDV (RR 0.95, 95% CI 0.81-1.11), HCQ (RR 1.19, 95% CI 0.89-1.59); LPV/r (RR 1.00, 95% CI 0.79-1.25) and IFN (RR 1.16, 95% CI 0.96-1.39); no signif
By vgreene, 20 October, 2020 Multinational, randomized study; 11,266 hospitalized pts (~10% ventilated) w/ COVID-19 received either RDV (n=2,750), HCQ (n=954), LPV/r (n=1,411), IFN beta 1a + LPV/r (n=651), IFN beta 1a (n=1,412) or SOC (n=4,088); pts could receive other therapies incl
